Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Authors / Anat Loewenstein

Anat Loewenstein

Anat Loewenstein, MD, MHA, is a professor and director of the Department of Ophthalmology, Vice Dean of the Faculty of Medicine, and Sidney Fox Chair of Ophthalmology at Tel Aviv University. She is also Chairman of Ophthalmology at Sourasky Medical Center in Tel Aviv and President of the Israeli Ophthalmological Society. Disclosures: Anat Loewenstein is a consultant to to Allergan, Bayer Healthcare, Beyeonics, Forsightlabs, NotalVision,Novartis, Roche, Syneos, Xbrane, Nanoretina, Ocuterra, Ripple Therapeutics, Annexon, MJHEvents, Iveric Bio, Biogen, Johnson & Johnson, Ocuphire Pharma, and Iqvia.

  • Contributions

We Need a Multipronged Strategy for nAMD

September 20, 2023

In addition to earlier detection and improved adherence to treatment, emerging drugs that more broadly target additional angiogenic factors may improve patient outcomes.

7 min read

We Need a Multipronged Strategy for nAMD

Our Time to Shine

September 21, 2021

My message to all existing and future Power List champions

1 min read

Our Time to Shine

Joining Forces for Diabetes

April 29, 2019

1 min read

Joining Forces for Diabetes
Sponsored

Shifting to a Systemic Approach

October 18, 2019

What does the future hold for the management – and treatment – of diabetic eye disease?

1 min read

Shifting to a Systemic Approach

Consider the Alternative

January 11, 2017

When it comes to treating retinal disease, VEGF isn’t the only game in town

1 min read

Consider the Alternative

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: